The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 Review
| Authors: | Ascierto, P. A.; Butterfield, L. H.; Finn, O. J.; Futreal, A.; Hamid, O.; LaVallee, T.; Postow, M. A.; Puzanov, I.; Sosman, J.; Fox, B. A.; Hwu, P. |
| Review Title: | The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021 |
| Abstract: | As part of the 2021 Immunotherapy Bridge virtual congress (December 1–2, Naples, Italy), the Great Debate sessions featured experts who were assigned counter opposing views on four important questions in immunotherapy today. The first topic was whether oncolytic viruses or other specific immunomodulators were the more promising approach for intralesional therapy. The second was whether early surrogate endpoints, such as response rate or progression-free survival, correlate with long-term overall survival was considered. Thirdly, whether vaccines can transform cold into hot tumors was discussed and, finally, broad versus deep analytic profiling approaches to gain insights into immune-oncology development were compared. As with previous Bridge congresses, presenters were invited by the meeting Chairs and positions taken during the debates may not have reflected their respective personal view. In addition, the views summarised in this article are based on available evidence but may reflect personal interpretation of these data, clinical experience and subjective opinion of the speaker. © 2022, The Author(s). |
| Keywords: | treatment response; unclassified drug; overall survival; sorafenib; antineoplastic agent; ipilimumab; ticilimumab; cancer immunotherapy; melanoma; progression free survival; evidence based practice; pathology; oncology; immunotherapy; cancer vaccine; cancer immunization; oncolytic virus; medical oncology; liver cancer; immunomodulating agent; immunologic factors; clinical trials; immunologic factor; metastatic melanoma; progression-free survival; triple negative breast cancer; sipuleucel t; dabrafenib; trametinib; nivolumab; talimogene laherparepvec; humans; human; article; metastatic castration resistant prostate cancer; pembrolizumab; durvalumab; checkpoint inhibitors; pexastimogene devacirepvec; bnt 111; bo 112; tavokinogene telseplasmid; tilsotolimod; vidutolimod |
| Journal Title: | Journal of Translational Medicine |
| Volume: | 20 |
| ISSN: | 1479-5876 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2022-04-21 |
| Start Page: | 179 |
| Language: | English |
| DOI: | 10.1186/s12967-022-03384-w |
| PUBMED: | 35449104 |
| PROVIDER: | scopus |
| PMCID: | PMC9022317 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 June 2022 -- Source: Scopus |
